Page 11 - Chris Viehbacher News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biogen drops Aduhelm efforts after controversial speedy approval

Biogen drops Aduhelm efforts after controversial speedy approval
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesChris viehbacherReata pharmaceuticalsCenters for medicare medicaid servicesMedicaid servicesHealthcare conferenceTexas based reata pharmaceuticals

After 40% reduction in force, Sage will shift to a smaller HQ

After 40% reduction in force, Sage will shift to a smaller HQ
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Charles riverUnited statesUnited kingdomAl robichaudJim dohertyBarry greeneChris viehbacherTime magazineSage therapeuticsFlagship pioneeringHealthcare conference

Slow Market Penetration For Biogen s Another Alzheimer s Drug: UBS Highlights Risks, Forecasts - Biogen (NASDAQ:BIIB)

UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.

Skyclarys friedreichChris viehbacherReata pharmaceuticals incRegeneron pharmaceuticals incBiogen incVertex pharmaceuticals incorporatedMild cognitive impairmentMild alzheimerEvolving landscape for alzheimerBlood tests gains momentum amid inaccuracyReata pharmaceuticalsRegeneron pharmaceuticalsVertex pharmaceuticals

27 Best Stocks to Buy Now, According to Our Roundtable Investment Pros

Meta Platforms, Diamondback Energy, Sphere Entertainment, and more stock picks from five of our Roundtable panelists.

United statesSaudi arabiaUnited kingdomDevry universityNew jerseySouth koreaNew yorkStacy skinnerAbby joseph cohenDavid girouxMark zuckerbergLas vegasMario gabelliTodd ahlstenChris viehbacherHenry ellenbogen

Biogen Bows Out of Acorda Pact on MS Med; Focus Turns to New Growth Drivers

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

San franciscoUnited statesFampyra ampyraChris viehbacherReata pharmaceuticalsEuropean medicines agencyAcorda therapeuticsNew york based acordaHealthcare conferenceReata friedreichWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsLife sciences